New treatment approaches in primary central nervous system lymphoma

Hematology/Oncology Clinics of North America

Volumn 19, Issue 4, 2005, Pages 719-728

  Soussain, Carole ^a   Hoang Xuan, Khê ^b   Doolittle, Nancy D ^c  

^a CENTRE HOSPITALIER DE MEAUX   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN G1 ANTIBODY; MELPHALAN; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; SODIUM THIOSULFATE; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINCRISTINE; VINCRISTINE SULFATE;

BACKACHE; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILL; CLINICAL TRIAL; HEARING LOSS; HUMAN; NAUSEA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PARAPLEGIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RELAPSE; REVIEW; STEM CELL TRANSPLANTATION;

EID: 23244444183     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.05.007     Document Type: Review

References (40)

1. J.Y. Blay, D. Bouhour, and C. Carrie The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression Blood 86 8 1995 2922 2929
2. M. Sarazin, A. Ameri, and A. Monjour Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy Eur J Cancer 31 12 1995 2003 2007
3. L.M. DeAngelis, W. Seiferheld, and S. Clifford Schold Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10 J Clin Oncol 20 2002 4643 4648
4. H. Pels, I.G.H. Schmidt-Wolf, and A. Glasmacher Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy J Clin Oncol 21 24 2003 4489 4495
5. H. Harder, H. Holtel, and J.E.C. Bromberg Cognitive status and quality of life after treatment for primary CNS lymphoma Neurology 62 2004 544 547
6. L. Fisher, E. Thiel, and H.A. Klasen Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan Neurology 62 2004 1885 1887
7. M. Reni, W. Mason, and F. Zaja Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial Eur J Haematol 40 2004 1683 1688
8. H. Schultz, H. Pels, and I. Schmidt-Wolf Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab Haematologica 89 2004 753 754
9. E.T. Wong, R. Tishler, and L. Barron Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas Cancer 101 1 2004 139 145
10. R.H. Enting, A. Demopoulos, and L.M. DeAngelis Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide Neurology 63 5 2004 901 903
11. E.S. Newlands, M.F. Stevens, and S.R. Wedge Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 1 1997 35 61
12. S.D. Baker, R.L. Heidemann, and W.R. Crom Cerebrospinal fluid pharmacokinetics and penetration of continuous topotecan in children with central nervous system tumors Cancer Chemother Pharmacol 37 1996 195 202
13. B. Coiffier, E. Lepage, and J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 4 2002 235 242
14. J.W. Grant, and P.G. Isaacson Primary central nervous system lymphoma Brain Pathol 2 1992 97 109
15. K. Schweichheimer, D.F. Braus, and G. Schwarzkopf Polymorphous high-grade B cell lymphoma is the predominant type of spontaneous primary cerebral malignant lymphomas: histological and immunomorphological evaluation of computed tomography-guided stereotactic brain biopsies Am J Surg Pathol 18 1994 931 937
16. E.A. Neuwelt, and P.A. Barnett Blood-brain barrier disruption in the treatment of brain tumors: animal studies E.A. Neuwelt Implications of the blood-brain barrier and its manipulation 1989 Plenum Publishing Corporation New York 109
17. A. Harjunpaa, T. Wiklund, and J. Collan Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma Leuk Lymphoma 42 2001 731 738
18. J.L. Rubenstein, D. Combs, and J. Rosenberg Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment Blood 101 2003 466 468
19. P. Feugier, J.M. Virion, and H. Tilly Incidence and risk factors for CNS occurrence in elderly patients with diffuse large B-cell lymphoma: influence of rituximab Ann Oncol 15 2004 129 133
20. R.M. Tyson, T. Siegal, and N.D. Doolittle Current status and future of relapsed primary central nervous system lymphoma (PCNSL) Leuk Lymphoma 44 4 2003 627 633
21. B.P. O'Neill, R.P. Dinapoli, and P.J. Kurtin Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? J Neurooncol 25 1 1995 67 71
22. T. Philip, C. Guglielmi, and A. Hagenbeek Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 23 1995 1540 1545
23. C. Soussain, F. Suzan, and K. Hoang-Xuan Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma J Clin Oncol 19 2001 742 749
24. C. Patte, A. Auperin, and J. Michon The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia Blood 97 11 2001 3370 3379
25. R.L. Heideman, D.E. Cole, and F. Balis Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa Cancer Res 49 3 1989 736 741
26. F.M. Balis, and D.G. Poplack Central nervous system pharmacology of antileukemic drugs Am J Pediatr Hematol Oncol 11 1 1989 74 86
27. M.R.Z. Talha, H.J. Rogers, and J.R. Trounce Distribution and pharmacokinetics of cyclophosphamide in the rat Br J Cancer 41 1980 140 143
28. D. Przepiorka, R. Nath, and C. Ippoliti A phase I-II studies of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma Leuk Lymphoma 17 5-6 1995 427 433
29. C. Haioun, E. Lepage, and C. Gisselbrecht Survival benefit of high dose therapy of poor-risk non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol, a Groupe d'Etude des Lymphomes de l'Adulte study J Clin Oncol 18 2000 3025 3030
30. L.E. Abrey, C.H. Moskowitz, and W.P. Mason Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis J Clin Oncol 21 2003 4151 4156
31. T. Cheng, P. Forsyth, and A. Chaudhry High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma Bone Marrow Transplant 31 2003 679 685
32. E. Arellano-Rodrigo, A. López-Guillermo, and E.M. Bessel Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma Eur J Haematol 70 2003 219 224
33. E.A. Neuwelt, D.L. Goldman, and S.A. Dahlborg Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function J Clin Oncol 9 9 1991 1580 1590
34. D.F. Kraemer, D. Fortin, and N.D. Doolittle Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival Neurosurgery 48 5 2001 1033 1040
35. L.D. McAllister, N.D. Doolittle, and P.E. Guastadisegni Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma Neurosurgery 46 1 2000 51 60
36. N.D. Doolittle, L.L. Muldoon, and R.E. Brummett Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors Clin Cancer Res 7 2001 493 500
37. L.L. Muldoon, M.A. Pagel, and R.A. Kroll Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity Clin Cancer Res 6 1 2000 309 315
38. H.J. Zhu, and G.Q. Liu Effects of E6, a novel calmodulin inhibitor, on activity of P-glycoprotein in purified primary cultured rat brain microvessel endothelial cells Acta Pharmacol Sin 24 11 2003 1143 1149
39. E.M. Kemper, W. Boogerd, and I. Thuis Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 30 5 2004 415 423
40. Smith Q.R. Overview of blood-brain barrier delivery of anticancer drugs. Presented at the 10th Annual Meeting of New Frontiers in Translational Research in Neuro-Oncology and the Blood-Brain Barrier. Sunriver (OR), March 17-24, 2004